Share issue
June 2019
Oncopeptides has completed a directed share issue of approximately SEK 727 million (USD 78 M)
June 28, 2019 – Regulatory press release
Oncopeptides AB (publ) announces that the Company has successfully completed a directed share issue of approximately SEK 727 million (USD 78 M).
The board of directors of Oncopeptides has, based on the issue authorization granted by the annual general meeting on 21 May 2019, and as indicated in the Company’s press release on 27 June 2019, resolved on a directed share issue of 5,015,000 new shares (the “New Shares”) at a subscription price of SEK 145 per share (the “Issue”), which means that the Company will receive gross proceeds of approximately SEK 727 million (USD 78 M).
Oncopeptides intends to carry out a directed share issue
June 27, 2019 – Regulatory press release
Oncopeptides AB (publ) announces its intention to execute a directed share issue to institutional investors (the “Issue”). The Company has retained Carnegie Investment Bank AB (publ), Cowen and Company LLC, DNB Markets, a part of DNB Bank ASA, Jefferies International Limited and Kempen & Co N.V. to act as Joint Bookrunners (the “Joint Bookrunners”) in connection with the Issue. Bookbuilding will start immediately following this announcement.
The subscription price and the total number of new shares in the Issue (the “Issue Shares”) will be determined through an accelerated bookbuild process (the “Bookbuilding”). It is intended that the number of newly issued shares will amount to approximately 10 percent of the total number of shares in the Company.